The introduction of computational methods into drug discovery marked a profound shift in the pharmaceutical and biotech industries.
Nanocarriers have demonstrated high effectiveness in delivering drugs and genes to the brain due to their unique properties.
The saga of antimicrobial peptides unfolds as a testament to scientific ingenuity and therapeutic resilience.
Researchers are utilizing adenine analogs to create potent inhibitors and agonists, targeting vital cellular pathways from cancer to infectious diseases.
Scientists are striving to understand bioavailability complexities to ensure the equivalence of drug formulations from different manufacturers, crucial for clinical effectiveness.
In the third part of the Biopharm and PK PharmaFEATURES Primer, we take a deeper dive in mathematical modeling to better estimate drug dosing and generate better predictions of drug efficacy vs time of medications.
Bioavailability, fundamental in pharmacology, explores intricate drug absorption and distribution in the body.
Plasma drug concentrations monitoring allows medication dose adjustment for individualized and optimized drug therapies.
A drug’s physicochemical properties play a crucial role in their effectiveness and safety.
QSAR promises to improve serotonin studies.
Understanding drug toxicity mechanisms is vital for patient safety and treatment efficacy.
The path from target identification to hit discovery showcases the scientific community’s ingenuity and perseverance.
This FBDD article discusses its fundamental principles, workflow, library selection criteria, expansion strategies, and optimization approaches.
Let’s explore how advanced technologies are actively transforming biomedical discovery, particularly in cancer research.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settings